---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-178937"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:43:26.729204+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pliant reports positive Phase 2a data for bexotegrast in PSC; 320 mg well tolerated up to 40 weeks

## Summary
- 320 mg cohort met primary safety endpoint; no treatment-related severe or serious adverse events.
- Improvement in liver stiffness by transient elastography at Week 24 vs placebo.
- Statistically significant reduction in alkaline phosphatase (ALP) over 24 weeks vs placebo.
- MRI showed continued improvement in hepatocyte function and bile flow from Week 12 to 24.
- FDA supportive of 52-week Phase 2b trial with non-invasive endpoints; program path being evaluated.

## SEC filing metadata
- accession: 0001193125-24-178937
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312524178937/0001193125-24-178937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312524178937/d829862d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-178937
- JSON: https://secwatch.observer/filing/0001193125-24-178937.json
- Plain text: https://secwatch.observer/filing/0001193125-24-178937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.